CLINICAL RESEARCH: FOCUS ISSUE: SUBSTUDIES FROM EX: TRACT-TIMI 25
The Impact of Renal Dysfunction on Outcomes in the ExTRACT-TIMI 25 Trial
Keith A.A. Fox, FRCP*,1,
Elliott M. Antman, MD, FACC ,1,*,
Gilles Montalescot, MD ,1,
Stefan Agewall, MD ,
Bhupathi SomaRaju, MD||,
Freek W.A. Verheugt, MD, FACC¶,
Jose Lopez-Sendon, MD, FACC#,
Hanoch Hod, MD, FACC**,
Sabina A. Murphy, MPH and
Eugene Braunwald, MD, MACC,1
* University of Edinburgh, Edinburgh, United Kingdom
TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts
Institut de Cardiologie, Pitie-Salpetriere University Hospital, Paris, France
Coronary Care Unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden
|| CARE Hospital, Hyderabad, India
¶ University Hospital Nijmegen, Nijmegen, the Netherlands
# Hospital Universitario La Paz Madrid, Madrid, Spain
** Heart Institute, Sheba Medical Center, Tel Hashomer, Israel.
Manuscript received September 7, 2006;
revised manuscript received December 5, 2006,
accepted December 10, 2006.
* Reprint requests and correspondence: Dr. Elliott M. Antman, TIMI Study Group, 350 Longwood Avenue, First Floor, Boston, Massachusetts 02115. (Email: eantman{at}rics.bwh.harvard.edu).
Objectives: The ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment–Thrombolysis In Myocardial Infarction 25) trial provided the opportunity to evaluate the impact of renal dysfunction on outcomes in patients with ST-segment elevation myocardial infarction (STEMI) and compare enoxaparin (ENOX) and unfractionated heparin (UFH).
Background: It is unclear how renal dysfunction influences the balance between benefit and risk of antithrombotic therapy.
Methods: In the ExTRACT-TIMI 25 trial, 20,479 patients were randomized to UFH or ENOX. A reduced ENOX dose was administered to patients age  75 years and those with an estimated creatinine clearance (CrCl) <30 ml/min.
Results: A powerful relationship was observed between the severity of renal dysfunction (per 10 ml/min decrement in CrCl) and death, stroke, intracranial hemorrhage, and major and minor bleeding (p < 0.001 for each). There was a progressive increase in the treatment benefit with ENOX on death or nonfatal myocardial infarction (p < 0.01) with better renal function. Net clinical benefit (death, nonfatal MI, or nonfatal major bleeding) was significantly superior with ENOX (p < 0.001) for patients with a CrCl >60 ml/min (79.1% of the study population). Major bleeding and intracranial hemorrhage did not differ for patients with preserved renal function (CrCl >90 ml/min), but in those with renal dysfunction there was a progressively greater increase in the risk of major and minor bleeding with ENOX.
Conclusions: Enoxaparin was superior to UFH for the majority of subjects. With more severe renal dysfunction, the net clinical benefit between ENOX and UFH did not differ, despite the rise in adverse events in both treatment groups. Future studies should take renal dysfunction into account when assessing antithrombotic regimens.
|
Abbreviations and Acronyms
| | CI = confidence interval | | CrCl = creatinine clearance | | ENOX = enoxaparin | | LMWH = low-molecular-weight heparin | | MI = myocardial infarction | | ORadj
= adjusted odds ratio | | STEMI = ST-segment elevation myocardial infarction | | UFH = unfractionated heparin |
|
This article has been cited by other articles:
|
|
|
|
 
S. S. Basra, P. Tsai, and N. M. Lakkis
Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease
J. Am. Coll. Cardiol.,
November 22, 2011;
58(22):
2263 - 2269.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Brown, B. Joshi, N. Faraday, A. Shah, D. Yuh, J. J. Rade, and C. W. Hogue
Review Article: Emergency Cardiac Surgery in Patients with Acute Coronary Syndromes: A Review of the Evidence and Perioperative Implications of Medical and Mechanical Therapeutics
Anesth. Analg.,
April 1, 2011;
112(4):
777 - 799.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Sederholm Lawesson, T. Todt, J. Alfredsson, M. Janzon, U. Stenestrand, and E. Swahn
Gender difference in prevalence and prognostic impact of renal insufficiency in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention
Heart,
February 15, 2011;
97(4):
308 - 314.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. O'Connor, L. Bossaert, H.-R. Arntz, S. C. Brooks, D. Diercks, G. Feitosa-Filho, J. P. Nolan, T. L. V. Hoek, D. L. Walters, A. Wong, et al.
Part 9: Acute Coronary Syndromes: 2010 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations
Circulation,
October 19, 2010;
122(16_suppl_2):
S422 - S465.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. James, A. Budaj, P. Aylward, K. K. Buck, C. P. Cannon, J. H. Cornel, R. A. Harrington, J. Horrow, H. Katus, M. Keltai, et al.
Ticagrelor Versus Clopidogrel in Acute Coronary Syndromes in Relation to Renal Function: Results From the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Circulation,
September 14, 2010;
122(11):
1056 - 1067.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. P. Dobesh and T. C. Trujillo
Anticoagulation in the Management of ST-Segment Elevation Myocardial Infarction
Journal of Pharmacy Practice,
August 1, 2010;
23(4):
335 - 343.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Agrawal, B. Rai, J. Fellows, and P. A. McCullough
In-hospital outcomes with thrombolytic therapy in patients with renal dysfunction presenting with acute ischaemic stroke
Nephrol. Dial. Transplant.,
April 1, 2010;
25(4):
1150 - 1157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Marcoff, Z. Zhang, W. Zhang, E. Ewen, C. Jurkovitz, P. Leguet, P. Kolm, and W. S. Weintraub
Cost Effectiveness of Enoxaparin in Acute ST-Segment Elevation Myocardial Infarction: The ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) Study
J. Am. Coll. Cardiol.,
September 29, 2009;
54(14):
1271 - 1279.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. P. Bonaca, P. G. Steg, L. J. Feldman, J. F. Canales, J. J. Ferguson, L. Wallentin, R. M. Califf, R. A. Harrington, and R. P. Giugliano
Antithrombotics in Acute Coronary Syndromes
J. Am. Coll. Cardiol.,
September 8, 2009;
54(11):
969 - 984.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Cannon
Should We Manage Patients With Non-ST Segment Elevation Myocardial Infarction With Renal Failure With an Invasive Strategy?
Circulation,
September 8, 2009;
120(10):
828 - 830.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. A Nutescu, S. A Spinler, A. Wittkowsky, and W. E Dager
Low-Molecular-Weight Heparins in Renal Impairment and Obesity: Available Evidence and Clinical Practice Recommendations Across Medical and Surgical Settings
Ann. Pharmacother.,
June 1, 2009;
43(6):
1064 - 1083.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Ilyas, N. Dhaun, D. Markie, P. Stansell, J. Goddard, D.E. Newby, and D.J. Webb
Renal function is associated with arterial stiffness and predicts outcome in patients with coronary artery disease
QJM,
March 1, 2009;
102(3):
183 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Dumaine, M. Borentain, O. Bertel, C. Bode, R. Gallo, H. D. White, J.-P. Collet, S. R. Steinhubl, and G. Montalescot
Intravenous Low-Molecular-Weight Heparins Compared With Unfractionated Heparin in Percutaneous Coronary Intervention: Quantitative Review of Randomized Trials
Arch Intern Med,
December 10, 2007;
167(22):
2423 - 2430.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
